ワシントンにおける黄斑変性症の臨床試験
ワシントン内の拠点で、黄斑変性症に関する8件の研究が参加者を募集しています。
ワシントン内の都市
公式研究テキスト（英語）
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
- Pacific Northwest Retina (Site 112), Burlington
- Spokane Eye Clinical Research (Site 075), Spokane
被験者募集中第2/3相
50歳以上 · 全性別 · 2026/10/02更新 · NCT07440225A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
- Spokane Eye Clinical Research, Spokane
被験者募集中第2/3相
60歳以上 · 全性別 · 2026/09/30更新 · NCT06635148A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Spokane Eye Clinic, Spokane
被験者募集中第1/2相
55歳以上 · 全性別 · 2026/09/23更新 · NCT07029945A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- Spokane Eye Clinical Research, Spokane
被験者募集中第3相
50歳〜85歳 · 全性別 · 2026/09/18更新 · NCT06541704Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
- Pacific Northwest Retina, Bellevue
- Pacific Northwest Retina, PLLC, Silverdale
被験者募集中第2相
55歳以上 · 全性別 · 2026/09/10更新 · NCT06659445A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- Spokane Eye Clinical Research, Spokane
被験者募集中第1相
50歳以上 · 全性別 · 2026/09/03更新 · NCT03178149A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
- Pacific Northwest Retina, Bellevue
被験者募集中第2/3相
50歳以上 · 全性別 · 2026/08/06更新 · NCT07496567Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Pacific Northwest Retina, Silverdale
被験者募集中第3相
50歳以上 · 全性別 · 2026/04/16更新 · NCT07064759ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。